KCNH2 and ventricular fibrillation: It is well known that Kv11.1 blockers can be associated with prolongation of the QT (Long QT; LQT) interval in the heart’s electrical cycle which is a marker for ventricular fibrillation and a risk factor for sudden death [89–91].